The pattern and rates of metabolism of maternal plasma dehydroisoandrosterone sulfate in human pregnancy

J. D. Madden, P. K. Siiteri, P. C. MacDonald, N. F. Gant

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

The present study was done to map the metabolic pathways and rates of maternal plasma clearance of dehydroisoandrosterone sulfate (MCRDS) in pregnancy. In the present study, maternal plasma dehydroisoandrosterone sulfate (DS) metabolism was largely accounted for by two major pathways not present or not prominent in the nonpregnant woman. The first major pathway was clearance of maternal plasma DS by placental aromatization of DS to form estradiol (E2). This pathway accounted for approximately 35 per cent of the total clearance. The second major pathway of metabolism of maternal plasma DS was by 16α-hydroxylation within the maternal compartment. This pathway accounted for approximately 32 per cent of maternal plasma DS clearance. Two other minor pathways of DS metabolism, that is, loss to the fetus and excretion as unaltered DS into urine, accounted for less than 1 per cent of total metabolism in each instance. The final pathway of DS metabolism was excretion as neutral steroids such as urinary 17-ketosteroids and other undefined losses. By combining the rate of DS clearance (MCRDS) from maternal plasma via all pathways with that fraction of DS removed uniquely by placental conversion of DS to estradiol (DS→E2), the placental clearance of DS→E2 (PCDSE2) may be measured. The measurement of PCDSE2 may be expected to reflect uteroplacental perfusion and as such may provide an investigative tool capable of assessing the dynamics of uteroplacental function in a variety of clinical conditions.

Original languageEnglish (US)
Pages (from-to)915-920
Number of pages6
JournalAmerican Journal of Obstetrics and Gynecology
Volume125
Issue number7
StatePublished - Aug 1 1976

Fingerprint

Dehydroepiandrosterone Sulfate
Mothers
Pregnancy
Estradiol
17-Ketosteroids
Hydroxylation
Metabolic Networks and Pathways
Fetus

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

The pattern and rates of metabolism of maternal plasma dehydroisoandrosterone sulfate in human pregnancy. / Madden, J. D.; Siiteri, P. K.; MacDonald, P. C.; Gant, N. F.

In: American Journal of Obstetrics and Gynecology, Vol. 125, No. 7, 01.08.1976, p. 915-920.

Research output: Contribution to journalArticle

Madden, J. D. ; Siiteri, P. K. ; MacDonald, P. C. ; Gant, N. F. / The pattern and rates of metabolism of maternal plasma dehydroisoandrosterone sulfate in human pregnancy. In: American Journal of Obstetrics and Gynecology. 1976 ; Vol. 125, No. 7. pp. 915-920.
@article{4e50c082135c4a9aac2d81227d8fbb12,
title = "The pattern and rates of metabolism of maternal plasma dehydroisoandrosterone sulfate in human pregnancy",
abstract = "The present study was done to map the metabolic pathways and rates of maternal plasma clearance of dehydroisoandrosterone sulfate (MCRDS) in pregnancy. In the present study, maternal plasma dehydroisoandrosterone sulfate (DS) metabolism was largely accounted for by two major pathways not present or not prominent in the nonpregnant woman. The first major pathway was clearance of maternal plasma DS by placental aromatization of DS to form estradiol (E2). This pathway accounted for approximately 35 per cent of the total clearance. The second major pathway of metabolism of maternal plasma DS was by 16α-hydroxylation within the maternal compartment. This pathway accounted for approximately 32 per cent of maternal plasma DS clearance. Two other minor pathways of DS metabolism, that is, loss to the fetus and excretion as unaltered DS into urine, accounted for less than 1 per cent of total metabolism in each instance. The final pathway of DS metabolism was excretion as neutral steroids such as urinary 17-ketosteroids and other undefined losses. By combining the rate of DS clearance (MCRDS) from maternal plasma via all pathways with that fraction of DS removed uniquely by placental conversion of DS to estradiol (DS→E2), the placental clearance of DS→E2 (PCDSE2) may be measured. The measurement of PCDSE2 may be expected to reflect uteroplacental perfusion and as such may provide an investigative tool capable of assessing the dynamics of uteroplacental function in a variety of clinical conditions.",
author = "Madden, {J. D.} and Siiteri, {P. K.} and MacDonald, {P. C.} and Gant, {N. F.}",
year = "1976",
month = "8",
day = "1",
language = "English (US)",
volume = "125",
pages = "915--920",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "7",

}

TY - JOUR

T1 - The pattern and rates of metabolism of maternal plasma dehydroisoandrosterone sulfate in human pregnancy

AU - Madden, J. D.

AU - Siiteri, P. K.

AU - MacDonald, P. C.

AU - Gant, N. F.

PY - 1976/8/1

Y1 - 1976/8/1

N2 - The present study was done to map the metabolic pathways and rates of maternal plasma clearance of dehydroisoandrosterone sulfate (MCRDS) in pregnancy. In the present study, maternal plasma dehydroisoandrosterone sulfate (DS) metabolism was largely accounted for by two major pathways not present or not prominent in the nonpregnant woman. The first major pathway was clearance of maternal plasma DS by placental aromatization of DS to form estradiol (E2). This pathway accounted for approximately 35 per cent of the total clearance. The second major pathway of metabolism of maternal plasma DS was by 16α-hydroxylation within the maternal compartment. This pathway accounted for approximately 32 per cent of maternal plasma DS clearance. Two other minor pathways of DS metabolism, that is, loss to the fetus and excretion as unaltered DS into urine, accounted for less than 1 per cent of total metabolism in each instance. The final pathway of DS metabolism was excretion as neutral steroids such as urinary 17-ketosteroids and other undefined losses. By combining the rate of DS clearance (MCRDS) from maternal plasma via all pathways with that fraction of DS removed uniquely by placental conversion of DS to estradiol (DS→E2), the placental clearance of DS→E2 (PCDSE2) may be measured. The measurement of PCDSE2 may be expected to reflect uteroplacental perfusion and as such may provide an investigative tool capable of assessing the dynamics of uteroplacental function in a variety of clinical conditions.

AB - The present study was done to map the metabolic pathways and rates of maternal plasma clearance of dehydroisoandrosterone sulfate (MCRDS) in pregnancy. In the present study, maternal plasma dehydroisoandrosterone sulfate (DS) metabolism was largely accounted for by two major pathways not present or not prominent in the nonpregnant woman. The first major pathway was clearance of maternal plasma DS by placental aromatization of DS to form estradiol (E2). This pathway accounted for approximately 35 per cent of the total clearance. The second major pathway of metabolism of maternal plasma DS was by 16α-hydroxylation within the maternal compartment. This pathway accounted for approximately 32 per cent of maternal plasma DS clearance. Two other minor pathways of DS metabolism, that is, loss to the fetus and excretion as unaltered DS into urine, accounted for less than 1 per cent of total metabolism in each instance. The final pathway of DS metabolism was excretion as neutral steroids such as urinary 17-ketosteroids and other undefined losses. By combining the rate of DS clearance (MCRDS) from maternal plasma via all pathways with that fraction of DS removed uniquely by placental conversion of DS to estradiol (DS→E2), the placental clearance of DS→E2 (PCDSE2) may be measured. The measurement of PCDSE2 may be expected to reflect uteroplacental perfusion and as such may provide an investigative tool capable of assessing the dynamics of uteroplacental function in a variety of clinical conditions.

UR - http://www.scopus.com/inward/record.url?scp=0017126649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017126649&partnerID=8YFLogxK

M3 - Article

C2 - 133611

AN - SCOPUS:0017126649

VL - 125

SP - 915

EP - 920

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 7

ER -